BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15897910)

  • 21. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
    Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
    Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Promoter methylation of ID4. A marker for recurrence-free survival in human breast cancer].
    Noetzel E; Veeck J; Horn F; Hartmann A; Knüchel R; Dahl E
    Pathologe; 2008 Nov; 29 Suppl 2():319-27. PubMed ID: 18807039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
    Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
    Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression.
    Ai L; Kim WJ; Kim TY; Fields CR; Massoll NA; Robertson KD; Brown KD
    Cancer Res; 2006 Aug; 66(16):7899-909. PubMed ID: 16912163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and promoter methylation of the RASSF1A gene in sporadic breast cancers in Chinese women.
    Li Y; Wei Q; Cao F; Cao X
    Oncol Rep; 2008 May; 19(5):1149-53. PubMed ID: 18425370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
    Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
    J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients.
    Taback B; Giuliano AE; Lai R; Hansen N; Singer FR; Pantel K; Hoon DS
    Ann N Y Acad Sci; 2006 Sep; 1075():211-21. PubMed ID: 17108214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
    Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
    Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer.
    Noetzel E; Veeck J; Niederacher D; Galm O; Horn F; Hartmann A; Knüchel R; Dahl E
    BMC Cancer; 2008 May; 8():154. PubMed ID: 18513385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas.
    Rønneberg JA; Tost J; Solvang HK; Alnaes GI; Johansen FE; Brendeford EM; Yakhini Z; Gut IG; Lønning PE; Børresen-Dale AL; Gabrielsen OS; Kristensen VN
    Cancer Res; 2008 Jul; 68(14):5562-71. PubMed ID: 18632608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
    Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
    Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer: progesterone receptor B hypermethylation in breast cancer.
    Mc Cormack O; Chung WY; Fitzpatrick P; Cooke F; Flynn B; Harrison M; Fox E; Gallagher E; McGoldrick A; Dervan PA; McCann A; Kerin MJ
    Breast Cancer Res Treat; 2008 Sep; 111(1):45-53. PubMed ID: 17896177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer.
    Bagadi SA; Prasad CP; Srivastava A; Prashad R; Gupta SD; Ralhan R
    Breast Cancer Res Treat; 2007 Sep; 104(3):277-86. PubMed ID: 17115114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines.
    Dowdy SC; Gostout BS; Shridhar V; Wu X; Smith DI; Podratz KC; Jiang SW
    Gynecol Oncol; 2005 Oct; 99(1):126-34. PubMed ID: 16023706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Epigenetic inactivation of microRNA genes in mammary carcinoma].
    Lehmann U; Hasemeier B; Römermann D; Müller M; Länger F; Kreipe H
    Verh Dtsch Ges Pathol; 2007; 91():214-20. PubMed ID: 18314617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic alterations associated with early stages of breast tumor metastasis.
    Ellsworth RE; Ellsworth DL; Patney HL; Deyarmin B; Hooke JA; Love B; Shriver CD
    Ann Surg Oncol; 2008 Jul; 15(7):1989-95. PubMed ID: 18401664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent down-regulation of HIVEP2 in human breast cancer.
    Fujii H; Gabrielson E; Takagaki T; Ohtsuji M; Ohtsuji N; Hino O
    Breast Cancer Res Treat; 2005 May; 91(2):103-12. PubMed ID: 15868437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer.
    Czekierdowski A; Czekierdowska S; Szymanski M; Wielgos M; Kaminski P; Kotarski J
    Neuro Endocrinol Lett; 2006 Oct; 27(5):609-13. PubMed ID: 17159813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promoter hypermethylation-mediated inactivation of LRRC4 in gliomas.
    Zhang Z; Li D; Wu M; Xiang B; Wang L; Zhou M; Chen P; Li X; Shen S; Li G
    BMC Mol Biol; 2008 Nov; 9():99. PubMed ID: 18976507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.